MK-677 Dosage Guide: Ibutamoren Protocol, Timing & Cycle Length (2026)

MK-677 (ibutamoren, also designated MK-0677 and L-163,191) is a non-peptide, orally active ghrelin receptor agonist and growth hormone secretagogue. Unlike injectable GHRPs such as ipamorelin or GHRP-6, MK-677 is a small molecule that mimics the action of ghrelin at the GHS-R1a receptor, stimulating pulsatile GH release and sustained IGF-1 elevation. Its oral bioavailability and 24-hour half-life make it unique among GH secretagogues — a single daily oral dose produces consistent, measurable GH and IGF-1 elevation, and no injection is required. MK-677 has been studied in published clinical trials for GH deficiency, muscle wasting, osteoporosis, and Alzheimer's disease, giving it an unusually robust human clinical data set compared to most research peptides. Dosage calibration remains important: the difference between the 10 mg and 25 mg dose ranges produces markedly different side effect profiles while offering diminishing incremental benefit.

Standard MK-677 Dosage Protocols

MK-677's clinical trial data provides unusually clear dosing guidance relative to most research peptides. Multiple published studies have used 10 mg, 25 mg, and 50 mg daily doses, with 25 mg being the most widely studied dose for GH/IGF-1 optimization:

The data from published trials (including those by Murphy et al. and Nass et al.) consistently show that 25 mg provides most of the IGF-1 benefit of 50 mg with substantially fewer side effects. The 10 mg dose is well-tolerated but produces more modest GH/IGF-1 responses. For most body composition and anti-aging research applications, 25 mg/day is the reference dose.

Important distinction: MK-677 is not a peptide — it is a non-peptide small molecule that mimics peptide action at the ghrelin receptor. Unlike injectable GHRPs, it does not require reconstitution, syringes, or cold storage. It is typically supplied as oral capsules or a liquid solution for research purposes.

Dosing Frequency & Timing

MK-677's ~24-hour half-life means once-daily dosing maintains consistent plasma levels and produces a sustained elevation in GH pulse amplitude and IGF-1. Splitting the dose is not required and provides no benefit over single daily dosing:

• Once daily — standard approach: Take at the same time each day. Consistency is more important than the specific time, but bedtime dosing is generally preferred (see below).
• Bedtime dosing (recommended): Taking MK-677 at night before sleep has two advantages: (1) It aligns GH stimulation with the natural nocturnal GH pulse, potentially amplifying total nightly GH output; (2) The hunger-stimulating effects of ghrelin receptor agonism are less disruptive during sleep than during waking hours — a practical consideration at higher doses.
• Morning dosing: Used when sleep disturbance or vivid dreams are a concern (occasional reports). Morning dosing is compatible with fasted states post-waking but may increase daytime hunger significantly.

Unlike injectable GH secretagogues, MK-677 does not require fasting for administration — it is active regardless of meal timing. However, the magnitude of the GH pulse may be modestly greater in a fasted state, consistent with ghrelin's known behavior.

Cycle Length

MK-677 has the most robust clinical trial cycle length data of any GH secretagogue in research use:

Short cycle (8–12 weeks)

Sufficient for assessing changes in IGF-1, body composition, sleep quality, and recovery markers. An 8-week cycle at 25 mg/day is the standard structure for performance-focused research applications. A 4-week washout is typical.

Standard cycle (12–16 weeks)

The most common research framework. 16 weeks provides sufficient time for meaningful changes in lean mass, fat mass, and bone remodeling markers. A 4–8 week washout follows before re-initiation.

Extended / long-term research

Published clinical trials have studied MK-677 for up to 12 months (Nass et al., 2008) and even 2 years. These long-term studies provide important safety data but are not typical frameworks for general research. Long-term IGF-1 monitoring is essential in extended protocols, as sustained supraphysiological IGF-1 carries theoretical long-term risks.

Note on continuous vs. cycled use

Some research frameworks use a 5-days-on/2-days-off pattern or continuous dosing without cycling, arguing that MK-677's mechanism does not cause receptor desensitization at standard doses. However, extended continuous use warrants careful biomarker monitoring, and the published safety data beyond 2 years is limited.

Reconstitution & Preparation

MK-677 does not require reconstitution for most research preparations:

• Oral capsules: Pre-measured doses (typically 10 mg or 25 mg per capsule). No preparation required. Store at room temperature away from moisture and heat.
• Liquid solution: Often supplied at 25 mg/mL in a PEG-400 or DMSO/ethanol carrier. Use the provided dropper or micropipette to measure the dose. Shake well before use. Refrigerate after opening if directed by the supplier.
• Raw powder: If weighing raw powder for research, use a precision milligram scale. MK-677 can be dissolved in DMSO, ethanol, or PEG-400 for solution preparation, or encapsulated. Stable as a powder at room temperature for extended periods if stored away from moisture.

Administration Guide

As an oral compound, MK-677 administration does not involve injection technique considerations. Key administration notes:

• With or without food: MK-677 can be taken with or without food. Taking with a small meal may reduce GI discomfort at higher doses.
• Avoid alcohol: Alcohol suppresses GH release and undermines the GH secretagogue effect. Evening alcohol consumption is particularly counterproductive in bedtime-dosed protocols.
• Consistent daily timing: Due to the 24-hour half-life, dosing at approximately the same time each day maintains stable trough levels and avoids day-to-day variability in GH/IGF-1 data.
• Dose titration in research: Starting at 10 mg/day for 1–2 weeks before advancing to 25 mg/day is a common titration approach to assess tolerance to hunger stimulation and water retention before committing to the standard research dose.

Stacking MK-677

MK-677's oral route and distinct ghrelin receptor mechanism make it compatible with injectable peptides that operate via different pathways:

• MK-677 + Ipamorelin or CJC-1295: A hybrid GH stack combining oral and injectable secretagogues. MK-677 provides sustained IGF-1 elevation while ipamorelin/CJC-1295 produces additional discrete GH pulses. The combination produces significantly elevated total GH output and is used in advanced GH research. Ipamorelin is typically dosed on its standard schedule (200–300 mcg 1–2× daily) alongside MK-677's once-daily dose. See the Ipamorelin + CJC-1295 Stack Guide.
• MK-677 + BPC-157: Used in recovery-focused research. MK-677 contributes the anabolic GH/IGF-1 signal; BPC-157 handles local tissue repair. No interaction expected between these independent mechanisms.
• MK-677 + GHK-Cu: In anti-aging and skin health research models. GHK-Cu's collagen synthesis effects and MK-677's systemic GH/IGF-1 elevation provide complementary anabolic signals. See the GHK-Cu Guide.

Side Effects & Safety Considerations

MK-677 has the most characterized side effect profile of any GH secretagogue due to its clinical trial data. Researchers should be aware of the following dose-dependent effects:

• Increased hunger/appetite: The most common and dose-dependent effect. MK-677 acts on ghrelin receptors, which regulate appetite, and increased hunger — especially at 25 mg and above — is reported by most research subjects. Particularly pronounced in the first 2–4 weeks. At 10 mg, hunger stimulation is typically manageable.
• Water retention and edema: GH-mediated aldosterone effects lead to fluid retention, particularly in the extremities (hands, feet, face). Typically most pronounced in weeks 1–3 and partially resolves as the body adapts. More significant at 25 mg vs. 10 mg. High sodium intake exacerbates this.
• Lethargy and fatigue: Some research subjects report increased fatigue, particularly at the 25–50 mg range. This may be related to the ghrelin-mediated sleep-promoting effects. Bedtime dosing often converts this from a side effect to a benefit (improved sleep quality).
• Vivid dreams or sleep disturbance: Reported especially at higher doses or when dosing in the evening. Usually resolves after 2–3 weeks. Switching to morning dosing can mitigate this.
• Mild numbness or tingling: Reported in clinical trials, particularly in extremities. Thought to be carpal tunnel-related fluid retention rather than a direct neurotoxic effect.
• Transient insulin resistance: MK-677 can transiently raise fasting blood glucose, particularly at higher doses. Published clinical trials document modest increases in fasting glucose and insulin levels. This is a key monitoring parameter in diabetic or metabolic research models.
• IGF-1 elevation: Consistent and dose-dependent. At 25 mg/day, IGF-1 typically increases 60–80% above baseline. Long-term implications of sustained IGF-1 elevation require monitoring.
• No impact on cortisol or prolactin: Unlike some GHRPs, MK-677 does not significantly raise cortisol or prolactin in published clinical studies at 25 mg/day.

Frequently Asked Questions